# The Effects of Empagliflozin on Arterial Wall Characteristics

Study · id `cardio:ct-nct03639545` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03639545](<https://clinicaltrials.gov/study/NCT03639545>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03639545

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

## Technical summary

Registry record NCT03639545. Randomized; triple masking; primary purpose treatment. Start 2018-03-01 (actual); primary completion 2018-12-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT03639545, source copy `cardio:ctgov-nct03639545-2018-08-21`, retrieved 2026-10-26)
- Started: 2018-03-01 (actual) (ClinicalTrials.gov record NCT03639545, source copy `cardio:ctgov-nct03639545-2018-08-21`, retrieved 2026-10-26)
- Primary completion: 2018-12-30 (anticipated) (ClinicalTrials.gov record NCT03639545, source copy `cardio:ctgov-nct03639545-2018-08-21`, retrieved 2026-10-26)
- Completion: 2019-01-30 (anticipated) (ClinicalTrials.gov record NCT03639545, source copy `cardio:ctgov-nct03639545-2018-08-21`, retrieved 2026-10-26)
- Countries: Slovenia (ClinicalTrials.gov record NCT03639545, source copy `cardio:ctgov-nct03639545-2018-08-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03639545-2018-08-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Effects of Empagliflozin on Arterial Wall Characteristics
- Condition: Vascular Stiffness
- Condition: Hypoglycemic Agents
- Condition: Diabetes Complications
- Condition: Diabetes Mellitus, Type 1
- Intervention (Drug): Empagliflozin 25mg
- Intervention (Drug): Metformin
- Intervention (Drug): Empagliflozin/Metformin
- Intervention (Drug): Placebos
- Lead sponsor: University Medical Centre Ljubljana
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry condition terms include this condition: Type 1 diabetes (`core:type-1-diabetes`)
- Registry lists this organization as the lead sponsor: University Medical Centre Ljubljana (`cardio:org-university-medical-centre-ljubljana`)

## Provenance

Content hash: 9d018ac96bde0d2b1bb1a2c5c6dcfe2b6e33714f508622bd3bddb1415197376a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
